Rehmann Capital Advisory Group Boosts Stock Position in Cencora, Inc. (NYSE:COR)

Rehmann Capital Advisory Group boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 4.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,541 shares of the company’s stock after acquiring an additional 59 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Cencora were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. New Millennium Group LLC purchased a new position in Cencora in the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter worth $30,000. Concord Wealth Partners acquired a new position in shares of Cencora during the third quarter worth about $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora during the second quarter worth about $36,000. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora during the third quarter worth about $41,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 93,018 shares of company stock worth $22,478,942 over the last ninety days. 15.80% of the stock is currently owned by corporate insiders.

Cencora Stock Up 0.1 %

COR opened at $232.16 on Friday. The firm has a market cap of $44.87 billion, a P/E ratio of 30.91, a PEG ratio of 1.62 and a beta of 0.45. The business’s fifty day simple moving average is $238.11 and its 200 day simple moving average is $233.82. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

Analyst Ratings Changes

A number of brokerages have weighed in on COR. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $276.80.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.